Cost of psoriasis patients treated with topiCals in franCe

Abstract

objectives: Psoriasis affects more than 3 million people in France. This bring the disease to a frequency that is comparable to other pathologies such as flu. In order to better understand the impact of psoriasis on patients’lives, a survey (BODBOT - Burden of Disease, Burden of Treatment) has been conducted by an independent agency. The questionnaire included questions on many dimension, such as: demographics, comorbidities, general self-perception, symptoms, diagnosis of severity (using broader categories than in the qualitative component, to be more reflective then a doctor’s diagnosis), relationships with health care professionals (HCPs), attitudes to treatments, attitudes to psoriasis and information seeking. A second study with objective to estimate the annual cost of treatment of psoriatic patients treated with topicals in France, from the perspective of the community was conducted based on the collected answers. methods: The processed data are from a survey by internet, BODBOT study, performed in 2011. 571 psoriasis patients participated in this survey in France. For the analysis of the economic aspects were studied responses from 529 patients treated only by local treatment. The database contains information on the prescription of topical treatments, medical and paramedical consultations reported by patients. These amounts were annualized and valued from the conventional nomenclature CNAMTS rates and prices of treatments derived from statistics based on GERS database updated in June 2012. A segmentation analysis of the annual cost was conducted to identify specific patterns of psoriatic patients whose annual cost is high. results: The average annual cost of care is estimated at €4,536 per patient (95% CI:[€3,636; €5,436]). 81% of this cost concerns local treatment prescribed by doctors. The misdiagnosis perceived, severity perceived by the patient, showing the character of psoriasis, severity diagnosed by the doctor, type of psoriasis and body surface area affected by psoriasis representing more than two palms increase significantly annual cost of care of patients treated with topicals. Were also highlighted the negative impact on the average annual cost of dissatisfaction with a bad relationship with the patient’s dermatologist and patient perception of an impaired quality of life. Conclusions: This study provides original results on the economic aspects of psoriasis, poorly documented in France.